Targeted inhibition of c-Met receptor by a selective c-Met inhibitor, Tivantinib, and a specific shRNA reduces breast cancer-derived bone metastases

被引：0
|
作者：
Previdi, Sara [1 ]
Abbadessa, Giovanni [2 ]
Dalo, Francesca [1 ]
France, Dennis S. [2 ]
Broggini, Massimo [1 ]
机构：
[1] Mario Negri Inst Pharmacol Res, Milan, Italy
[2] ArQule Inc, Woburn, MA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-846
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
    Previdi, Sara
    Abbadessa, Giovanni
    Dalo, Francesca
    France, Dennis S.
    Broggini, Massimo
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (01) : 214 - 223
  • [2] Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
    Breen, Laura
    Gaule, Patricia B.
    Canonici, Alexandra
    Walsh, Naomi
    Collins, Denis M.
    Cremona, Mattia
    Hennessy, Bryan T.
    Duffy, Michael J.
    Crown, John
    O' Donovan, Norma
    Eustace, Alex J.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1365 - 1372
  • [3] Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
    Laura Breen
    Patricia B. Gaule
    Alexandra Canonici
    Naomi Walsh
    Denis M. Collins
    Mattia Cremona
    Bryan T. Hennessy
    Michael J. Duffy
    John Crown
    Norma O’ Donovan
    Alex J. Eustace
    Investigational New Drugs, 2020, 38 : 1365 - 1372
  • [4] Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models
    Gavine, Paul R.
    Ren, Yongxin
    Han, Lu
    Lu, Jing
    Fan, Shiming
    Zhang, Wei
    Xu, Wen
    Liu, Yuan Jie
    Zhang, Tianwei
    Fu, Haihua
    Yu, Yongjuan
    Wang, Huiying
    Xu, Shirlian
    Zhou, Feng
    Su, Xinying
    Yin, XiaoLu
    Xie, Liang
    Wang, Linfang
    Qing, Weiguo
    Jiao, Longxian
    Su, Weiguo
    Wang, Q. May
    MOLECULAR ONCOLOGY, 2015, 9 (01) : 323 - 333
  • [5] C-Met in Invasive Breast Cancer
    Ho-Yen, Colan M.
    Green, Andrew R.
    Rakha, Emad A.
    Brentnall, Adam R.
    Ellis, Ian O.
    Kermorgant, Stephanie
    Jones, J. L.
    CANCER, 2014, 120 (02) : 163 - 171
  • [6] A selective inhibitor targeting c-Met receptor tyrosine kinase in gastric cancer
    Park, Byung Hee
    Yun, Sun-Mi
    Jung, Kyung Hee
    Lee, Hyunseung
    Hong, Soon-Sun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 350 - 350
  • [7] The c-Met receptor: Implication for targeted therapies in colorectal cancer
    Qamsari, Elmira Safaie
    Ghaderi, Sepideh Safaei
    Zarei, Bahareh
    Dorostkar, Ruhollah
    Bagheri, Salman
    Jadidi-Niaragh, Farhad
    Somi, Mohammad Hossein
    Yousefi, Mehdi
    TUMOR BIOLOGY, 2017, 39 (05)
  • [8] Modeling targeted inhibition of wild type and mutated c-MET receptor
    Ma, P. C.
    Jiang, S.
    Du, R.
    Dietrich, S.
    Tang, Z.
    Kern, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao, Shankun
    Wu, Weizhou
    Jiang, Hao
    Ma, Lei
    Pan, Chengyi
    Jin, Chong
    Mo, Jinggang
    Wang, Liezhi
    Wang, Kunpeng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] TIVANTINIB Proto-oncogene c-Met Inhibitor Hepatocyte Growth Factor Receptor Inhibitor Oncolytic
    Pento, J. Thomas
    DRUGS OF THE FUTURE, 2011, 36 (12) : 893 - 898
12345